Detalhe da pesquisa
1.
Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.
Int J Mol Sci
; 24(24)2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38139386
2.
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.
Ann Hematol
; 101(12): 2655-2663, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36269400
3.
Early and late stage MPN patients show distinct gene expression profiles in CD34+ cells.
Ann Hematol
; 100(12): 2943-2956, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34390367
4.
Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.
Haematologica
; 108(4): 1179-1185, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36453102
5.
Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.
Sci Rep
; 14(1): 2810, 2024 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308077
6.
Engineering Mesoscopic 3D Tumor Models with a Self-Organizing Vascularized Matrix.
Adv Mater
; 36(5): e2303196, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865947
7.
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms.
Blood Cancer Discov
; 3(4): 298-315, 2022 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35405004
8.
Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Cells
; 10(12)2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34944059
9.
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.
Cancers (Basel)
; 13(16)2021 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34439364
10.
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes.
Stem Cell Reports
; 16(11): 2768-2783, 2021 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34678208
11.
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Leukemia
; 34(4): 1062-1074, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728053
12.
Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.
J Hematol Oncol
; 12(1): 36, 2019 04 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30940163
13.
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
Leukemia
; 33(4): 995-1010, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30470838
14.
Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis.
Front Immunol
; 9: 1552, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30034396
15.
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms.
Blood Cancer J
; 13(1): 164, 2023 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37926720